Professor Bob Hancock | Former Associate Faculty

This person is a member of Sanger Institute Alumni.

Hancock, Bob

Bob Hancock's Associate Faculty position at the Sanger Institute has now ended and this page is being maintained as a historical record of his research at the Institute and is no longer being updated

Bob Hancock's research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance. At the Sanger Institute he is involved in the cellular phenotyping programme, converting mutated mouse embryonic stem cells and human induced pluripotent stem cells into macrophages with the aim of understanding functional networks of genes involved in infections and inflammation.

Bob Hancock is a Professor of Microbiology & Immunology, UBC, and a Canada Research Chair in Health and Genomics. Bob has published more than 660 papers and reviews, has 50 patents awarded, and is an ISI highly cited author in Microbiology with more than 63,000 citations and an h-index of 130. He has won several awards including the Aventis Pharmaceuticals Award, the leading award for research on antimicrobials, and Canada’s three top prizes for Health Research, and is an Officer of the Order of Canada. He was a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset, and the Centre for Drug Research and Development.


  • Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

    Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P et al.

    Nature 2000;406;6799;959-64

  • An anti-infective peptide that selectively modulates the innate immune response.

    Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M et al.

    Nature biotechnology 2007;25;4;465-72

  • InnateDB: facilitating systems-level analyses of the mammalian innate immune response.

    Lynn DJ, Winsor GL, Chan C, Richard N, Laird MR et al.

    Molecular systems biology 2008;4;218

  • Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria.

    Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L et al.

    Science translational medicine 2012;4;135;135ra64

  • The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiation.

    Nijnik A, Clare S, Hale C, Raisen C, McIntyre RE et al.

    Blood 2012;119;6;1370-9

  • Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells.

    Mayer ML, Blohmke CJ, Falsafi R, Fjell CD, Madera L et al.

    Journal of immunology (Baltimore, Md. : 1950) 2013;190;3;1227-38

  • Broad-spectrum anti-biofilm peptide that targets a cellular stress response.

    de la Fuente-Núñez C, Reffuveille F, Haney EF, Straus SK and Hancock RE

    PLoS pathogens 2014;10;5;e1004152

  • An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation.

    Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA et al.

    EBioMedicine 2014;1;1;64-71

  • Conditional-ready mouse embryonic stem cell derived macrophages enable the study of essential genes in macrophage function.

    Yeung AT, Hale C, Xia J, Tate PH, Goulding D et al.

    Scientific reports 2015;5;8908

  • NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data.

    Xia J, Gill EE and Hancock RE

    Nature protocols 2015;10;6;823-44

No image available
Bob's Timeline

Appointed Associate Faculty at Wellcome Trust Sanger Institute


Director of Genome Canada Grant working with WTSI scientists and a large multi-national team


Appointed Canada Research Chair


Scientific Director of Canadian Bacterial Diseases Network


Appointed Assistant Associate then full Professor at the University of British Colombia